Table 1. Baseline characteristics and... | American Society of Hematology

Table 1.

Baseline characteristics and evolution of PI⁻ patients receiving HAART

Patient	Baseline values			Antiretroviral regimen	Follow-up, months	VL after PI therapy, log₁₀ RNA copies/mm³^†	CD4 change		CD8 change
Patient	CD4, cells/mm³	CD8, cells/mm³	VL, log₁₀ RNA copies/mm³^*	Antiretroviral regimen	Follow-up, months	VL after PI therapy, log₁₀ RNA copies/mm³^†	M6, cells/mm³	M15, cells/mm³	M6, cells/mm³	M15, cells/mm³
1	53	747	4.73	ZDV, ddC, IDV	18	<2.30	+251	+275	+1782	+929
2	99	412	2.63	D4T, ddI, IDV	9	3.14	+204	ND	+439	ND
3	319	778	5.44	ZDV, 3tC, IDV	15	<2.3	+152	+461	−311	+89
4	493	493	5.51	ZDV, 3tC, IDV	18	<2.30	+362	+252	−14	−79
5	622	876	4.48	ZDV, 3tC, IDV^‡	18	2.98	+99	+240	−358	−410
6	159	935	5.06	ZDV, 3tC, IDV	9	<2.30	+180	ND	−50	ND
7	210	955	4.99	D4T, ddI, IDV	15	3.78	+83	+140	+120	+567
8	210	724	3.94	ZDV, 3tC, IDV	18	<2.30	+74	+100	+50	+215
9	230	2556	5.15	ZDV, 3tC, IDV	18	<2.30	+20	+170	−646	−976
10	247	433	4.44	D4T, 3tC, IDV	15	3.40	+95	+108	+102	+201
11	267	954	<2.30	d4T, ddI, IDV^‡	9	<2.30	+39	ND	−450	ND
12	312	800	3.56	D4T, 3tC, IDV	18	<2.30	−32	+102	−412	−481
13	380	1520	2.69	ZDV, 3tC, IDV	6	<2.30	+127	ND	−675	ND
14	383	709	<2.30	ZDV, 3tC, IDV	18	<2.30	+361	+522	−4	−278
15	600	1622	5.24	ZDV, ddC, IDV	18	<2.30	+120	+140	−530	−770

Patient	Baseline values			Antiretroviral regimen	Follow-up, months	VL after PI therapy, log₁₀ RNA copies/mm³^†	CD4 change		CD8 change
Patient	CD4, cells/mm³	CD8, cells/mm³	VL, log₁₀ RNA copies/mm³^*	Antiretroviral regimen	Follow-up, months	VL after PI therapy, log₁₀ RNA copies/mm³^†	M6, cells/mm³	M15, cells/mm³	M6, cells/mm³	M15, cells/mm³
1	53	747	4.73	ZDV, ddC, IDV	18	<2.30	+251	+275	+1782	+929
2	99	412	2.63	D4T, ddI, IDV	9	3.14	+204	ND	+439	ND
3	319	778	5.44	ZDV, 3tC, IDV	15	<2.3	+152	+461	−311	+89
4	493	493	5.51	ZDV, 3tC, IDV	18	<2.30	+362	+252	−14	−79
5	622	876	4.48	ZDV, 3tC, IDV^‡	18	2.98	+99	+240	−358	−410
6	159	935	5.06	ZDV, 3tC, IDV	9	<2.30	+180	ND	−50	ND
7	210	955	4.99	D4T, ddI, IDV	15	3.78	+83	+140	+120	+567
8	210	724	3.94	ZDV, 3tC, IDV	18	<2.30	+74	+100	+50	+215
9	230	2556	5.15	ZDV, 3tC, IDV	18	<2.30	+20	+170	−646	−976
10	247	433	4.44	D4T, 3tC, IDV	15	3.40	+95	+108	+102	+201
11	267	954	<2.30	d4T, ddI, IDV^‡	9	<2.30	+39	ND	−450	ND
12	312	800	3.56	D4T, 3tC, IDV	18	<2.30	−32	+102	−412	−481
13	380	1520	2.69	ZDV, 3tC, IDV	6	<2.30	+127	ND	−675	ND
14	383	709	<2.30	ZDV, 3tC, IDV	18	<2.30	+361	+522	−4	−278
15	600	1622	5.24	ZDV, ddC, IDV	18	<2.30	+120	+140	−530	−770

ND indicates not determined; ZDV, zidovudine; ddC, zalcitabine; IDV, indinavir; d4T, stavudine; ddI, didanosine; and 3TC, lamivudine. Patients 1-5 were naı̈ve of previous antiretroviral therapy, and patients 6-15 had previously been treated by RTIs.

Amplicor HIV-1 Monitor test (Roche, Branchburg, NJ) was used for a threshold of detection of 200 copies/mm³.

†

Values are given for the last point of follow-up.

‡

Therapy was changed from IDV to saquinavir (SQV) at M2.

View Large

This Feature Is Available To Subscribers Only